Eidos Therapeutics, a BridgeBio company
Quick facts
Phase 3 pipeline
- Acoramidis (AG10) · Rare disease / Cardiology
Acoramidis stabilizes transthyretin (TTR) protein to prevent its misfolding and aggregation, which causes amyloid disease. - AG10 oral tablet · Cardiovascular / Rare Disease
AG10 stabilizes transthyretin (TTR) protein to prevent its misfolding and aggregation, which causes amyloid deposition in cardiac and neurological tissues.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Eidos Therapeutics, a BridgeBio company portfolio CI brief
- Eidos Therapeutics, a BridgeBio company pipeline updates RSS
Frequently asked questions about Eidos Therapeutics, a BridgeBio company
What is Eidos Therapeutics, a BridgeBio company's pipeline?
Eidos Therapeutics, a BridgeBio company has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Acoramidis (AG10), AG10 oral tablet.
Related
- Sector hub: All tracked pharma companies